Forward Air (FWRD) surges 25.6% as EPS revision sparks rally
Upward EPS revisions drove significant gains. Forward Air (FWRD) climbed 25.6% after its estimate rose from 69.4% to 78.0%, AVITA Medical (RCEL) gained 22.9% on a revision to 48.4% EPS growth, and Aehr Test Systems (AEHR) added 15.4% as its estimate jumped to 119.6%. The rally underscores market appetite for estimate upgrades in industrials, healthcare, and technology.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FWRD | Industrials | 2026-07-14 | +8.6pp | +25.6% |
| RCEL | Healthcare | 2026-07-14 | N/A | +22.9% |
| AEHR | Technology | 2026-07-17 | +20.0pp | +15.4% |
| AIRS | Healthcare | 2026-07-14 | +5.2pp | +14.8% |
| LITE | Technology | 2026-07-17 | N/A | +13.2% |
Why did FWRD stock jump in July 2026?
FWRD jumped 25.6% (from $12.79 to $16.07) after analysts raised its forward EPS growth estimate from 69.4% to 78.0% on July 14.
The revision came ahead of the company's Q2 2026 earnings release scheduled for August 5. The asset-light transportation provider has seen improving sentiment as freight markets show signs of recovery. The screener detected the EPS upgrade before the price rally, capturing a 25.6% gain in just over a week.
FWRD EPS revision history → · Screener snapshot from 2026-07-14 →
FAQ: FWRD
Why did FWRD stock jump in July 2026?
FWRD surged 25.6% after analysts raised its forward EPS growth estimate by 8.6 percentage points to 78.0% on July 14, ahead of its Q2 earnings announcement.
Is FWRD a buy after the rally?
The EPS revision and positive news suggest continued optimism, but investors should monitor the August 5 earnings report for confirmation.
What caused FWRD's surge?
The surge was driven by a significant upward revision in EPS estimates and the announcement of upcoming earnings, reflecting improving fundamentals in the transportation sector.
Why did RCEL stock jump in July 2026?
RCEL jumped 22.9% (from $4.02 to $4.94) after analysts revised its next-year EPS growth estimate to 48.4% on July 14.
The company, a leader in acute wound care, also announced it would report Q2 2026 financial results on August 6. The revision signals growing confidence in AVITA Medical's revenue trajectory and market adoption of its regenerative skin technology. The screener identified the EPS upgrade early, resulting in a 22.9% gain.
RCEL EPS revision history → · Screener snapshot from 2026-07-14 →
FAQ: RCEL
Why did RCEL stock jump?
RCEL gained 22.9% after analysts boosted its next-year EPS growth estimate to 48.4% on July 14, ahead of its Q2 earnings release.
What is RCEL's EPS growth estimate?
RCEL's next-year EPS growth estimate stands at 48.4% after the upward revision.
Is AVITA Medical a buy?
The EPS upgrade and positive market reaction suggest bullish sentiment, but the stock's performance will depend on upcoming earnings.
Why did AEHR stock jump in July 2026?
AEHR jumped 15.4% (from $81.05 to $93.54) after analysts raised its forward EPS growth estimate from 99.6% to 119.6% on July 17.
Multiple analysts, including Freedom Broker, upgraded AEHR to Buy and raised price targets, citing AI-related semiconductor testing demand. The company's fiscal 2027 revenue guidance of $130-150 million far exceeded consensus. The screener captured the revision and subsequent price surge as market rewarded the strong outlook.
AEHR EPS revision history → · Screener snapshot from 2026-07-17 →
FAQ: AEHR
Why did AEHR stock jump in July 2026?
AEHR surged 15.4% after its EPS growth estimate was raised by 20 percentage points to 119.6%, supported by analyst upgrades and strong AI-related test equipment demand.
Is AEHR a buy after the rally?
Analysts see further upside with price targets up to $110, but the stock has already gained significantly this year.
What caused AEHR's surge?
The surge was triggered by a large EPS revision and bullish analyst notes highlighting AI-driven growth in semiconductor testing.
Why did AIRS stock jump in July 2026?
AIRS jumped 14.8% (from $4.20 to $4.82) after analysts raised its forward EPS growth estimate from 44.8% to 50.0% on July 14.
The revision for this body contouring company came without accompanying company-specific news, suggesting the move was driven by the estimate upgrade itself and possibly sector momentum in healthcare services. The screener's detection of the 5.2 percentage point EPS revision preceded the price increase.
AIRS EPS revision history → · Screener snapshot from 2026-07-14 →
FAQ: AIRS
Why did AIRS stock jump?
AIRS rose 14.8% after its EPS growth estimate was revised up 5.2 percentage points to 50.0% on July 14.
What is AIRS's EPS growth estimate?
AIRS's next-year EPS growth estimate is now 50.0%, up from 44.8%.
Is Airsculpt a good buy?
The EPS upgrade is positive, but the absence of news means investors should verify fundamentals before buying.
Why did LITE stock jump in July 2026?
LITE jumped 13.2% (from $732.82 to $829.70) after analysts revised its next-year EPS growth estimate to 125.2% on July 17.
Barclays upgraded Lumentum to Overweight, citing strong AI networking demand and improved earnings potential. The stock also benefited from a broad semiconductor rally after Alphabet raised spending targets. The EPS revision and analyst upgrade aligned, driving the 13.2% gain detected by the screener.
LITE EPS revision history → · Screener snapshot from 2026-07-17 →
FAQ: LITE
Why did LITE stock jump?
LITE rose 13.2% after its EPS growth estimate was set at 125.2%, supported by a Barclays upgrade and AI-related chip demand.
Is Lumentum a buy after the rally?
Analysts see more upside with a $1,000 price target, but the stock's high valuation warrants caution.
What caused LITE's surge?
The surge was driven by an EPS revision, a Barclays upgrade citing AI networking, and positive sector momentum from Alphabet's capex news.
Today's top performers show that earnings estimate revisions remain a powerful catalyst for short-term price gains. The concentration in industrials and technology suggests investors are betting on cyclical and AI-driven growth.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →